Open access

719 CD122-directed interleukin-2 complexes and αPD-L1 differentially require innate and adaptive immunity to treat local and metastatic bladder cancer
Ryan Reyes, Yilun Deng, Deyi Zhang, Niannian Ji, Neelam Mukherjee, Karen Wheeler, Harshita Gupta, Aravind Kancharla, Myrna Garcia, Anand Kornepati, Robert Svatek, Tyler Curiel

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A430-A431; DOI: 10.1136/jitc-2020-SITC2020.0719
722 Inhibition of integrin avß8-Mediated TGF-ß activation with C6D4 provides improved potency and selectivity vs general TGF-ß inhibitors for cancer immunotherapy
Robert Seed, Stephen Nishimura

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A432-A433; DOI: 10.1136/jitc-2020-SITC2020.0722
723 Lymph node-targeted AMP-vaccine enables tumor-directed mKRAS-specific immune responses with potent polyfunctional and cytolytic activity
Martin Steinbuck, Peter DeMuth, Lochana Seenappa

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A433; DOI: 10.1136/jitc-2020-SITC2020.0723
725 Pre-clinical development of TNFR2 ligand-blocking BI-1808 for cancer immunotherapy
Linda Mårtensson, Mathilda Kovacek, Petra Holmkvist, Monika Semmrich, Carolin Svensson, Therese Blidberg, Carl Roos, Andres McAllister, Mimoza Demiri, Marie Borggren, Ingrid Karlsson, Björn Frendeus, Ingrid Teige

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A434; DOI: 10.1136/jitc-2020-SITC2020.0725
728 Antibiotics and response to immunotherapy: real-world experience
Yasar Ahmed, Paula Calvert

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A435-A436; DOI: 10.1136/jitc-2020-SITC2020.0728
729 The impact of immune and targeted therapies for melanoma in asian populations: a national cancer database analysis 2004–2016
Lifen Cao, Kavin Sugumar, Ankit Mangla, Megan Miller, Luke Rothermel

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A436-A437; DOI: 10.1136/jitc-2020-SITC2020.0729
730 Histotripsy focused ultrasound ablation induces immunological cell death in treated and distant untreated tumors
Anutosh Ganguly, Ashley Pepple, Reliza McGinnis, Ryan Hubbard, Amy Felsted, Tejaswi Worlikar, Hannah Garavaglia, Joe Dib, Joe Guy, Michal Olszewski, Zhen Xu, Clifford Cho

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A437; DOI: 10.1136/jitc-2020-SITC2020.0730
734 A novel NQO1 specific anti-tumor agent, SBSC-S3001, selectively regresses the growth of tumors with high NQO1 expression
Minhyuk Yun, Goo-Young Kim, Sang Woo Jo, Changhoon In, Gyu-Young Moon, In Seok Ko, Eun Ju Lee, Yong Rae Hong, Whee Seong Lee, Helen Cho

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A439; DOI: 10.1136/jitc-2020-SITC2020.0734
735 Impact of reversing an epithelial-to-mesenchymal transition program on tumor metabolism and immune suppression
Michelle Williams, Jessica Christenson, Kathleen O’Neill, Sabrina Hafeez, Nicole Spoelstra, Jill Slansky, Jennifer Richer

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A440; DOI: 10.1136/jitc-2020-SITC2020.0735
739 Development of patient-derived models of esophageal cancer for GUCY2C-directed immunotherapeutic testing
Megan Weindorfer, Amanda Lisby, Alicja Zalewski, Trevor Baybutt, Robert Carlson, Madison Crutcher, David Loren, Ernest Rosato, Nathaniel Evans, Scott Waldman, Adam Snook

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A442-A443; DOI: 10.1136/jitc-2020-SITC2020.0739

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages